DICE Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DICE research report →
About the company
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics.
- CEO
- J. Kevin Judice
- IPO
- 2021
- Employees
- 71
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $2.27B
- P/E
- -22.97
- P/S
- 0.00
- P/B
- -9.99
- EV/EBITDA
- -21.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 56.07%
- ROIC
- -14.80%
- Revenue
- $0 · -100.00%
- Net Income
- $-81,664,000 · -68.48%
- EPS
- $-2.07 · 47.06%
- Op Income
- $-88,221,000
- FCF YoY
- -66.36%
- 52W High
- $47.90
- 52W Low
- $15.08
- 50D MA
- $42.26
- 200D MA
- $34.24
- Beta
- 0.00
- Avg Volume
- 1.75M
Get TickerSpark's AI analysis on DICE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 21,250 |
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | other | 786,407 |
| Aug 9, 23 | TETLOW SHARON | sell | 21,250 |
| Aug 9, 23 | TETLOW SHARON | sell | 49,841 |
| Aug 9, 23 | TETLOW SHARON | sell | 13,800 |
| Aug 9, 23 | Simson Jake | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 13,800 |
| Aug 9, 23 | Scopa James Paul | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 25,722 |
| Aug 9, 23 | Robertson Scott M. | sell | 56,920 |
Our DICE coverage
Recent articles, reports, and earnings notes.
No research on DICE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DICE report →Similar companies
Peers in the same neighborhood.